AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

Propane fuel exposure can cause COPD and lead to symptom flare-ups, due to the toxic fumes and chemicals it contains. You can stay alert by watching for symptoms and get medical care and treatment if ...

A pulmonary contusion or lung contusion is a bruise in or on your lungs caused by blunt force to the chest. It is different than the tearing of lung tissue because a pulmonary contusion doesn’t affect ...